Inmolecule NanotechXPAR:MLINA 6 PB Ratio is 4.14 as of Jul. 01, 2026. GuruFocus rates XPAR:MLINA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,229 Biotechnology companies, Inmolecule Nanotech ranks worse than 63.79% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Inmolecule Nanotech PB Ratio Related Terms
Inmolecule Nanotech PB Ratio Historical Data
* Premium members only.
The historical data trend for Inmolecule Nanotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inmolecule Nanotech PB Ratio Chart
Inmolecule Nanotech Annual Data
Trend
Dec23
Dec24
PB Ratio
0.00
0.00
Inmolecule Nanotech Semi-Annual Data
Dec23
Dec24
PB Ratio
0.00
0.00
XPAR:MLINA vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Inmolecule Nanotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inmolecule Nanotech PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inmolecule Nanotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Inmolecule Nanotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Inmolecule Nanotech (XPAR:MLINA) has a PB Ratio of 4.14 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Inmolecule Nanotech and its competitors. According to the industry distribution chart, Inmolecule Nanotech ranks #784 out of 1229 companies in the Biotechnology industry, placing it in the top 63.8%.
Is Inmolecule Nanotech's PB Ratio too high?
Inmolecule Nanotech's current PB Ratio is 4.14. The Biotechnology industry median PB Ratio is 2.86. Inmolecule Nanotech's value of 4.14 is 44.8% above this industry median. Based on the distribution chart, Inmolecule Nanotech ranks #784 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Inmolecule Nanotech has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Inmolecule Nanotech's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inmolecule Nanotech ranks #784 out of 1229 companies for PB Ratio. This places Inmolecule Nanotech in the lower half of its industry. The industry median PB Ratio is 2.86. Inmolecule Nanotech's value of 4.14 is 44.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.86, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inmolecule Nanotech's current PB Ratio of 4.14 is 44.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Inmolecule Nanotech and its competitors. For the Biotechnology industry, the median PB Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inmolecule Nanotech's current PB Ratio is 4.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inmolecule Nanotech stock overvalued right now?
Inmolecule Nanotech (XPAR:MLINA) has a current PB Ratio of 4.14. The current PB Ratio is 4.14 and 44.8% above the Biotechnology industry median of 2.86. Inmolecule Nanotech's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Inmolecule Nanotech (XPAR:MLINA), the current PB Ratio is 4.14 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLINA has been successfully added to your 